These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1531789)

  • 21. The effect of patient size and dose of recombinant human erythropoietin therapy on red blood cell volume expansion in autologous blood donors for elective orthopedic operation.
    Goodnough LT; Verbrugge D; Marcus RE; Goldberg V
    J Am Coll Surg; 1994 Aug; 179(2):171-6. PubMed ID: 8044386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Secondary effects of erythropoietin treatment on metabolism and dialysis efficiency in stable hemodialysis patients.
    Buur T; Lundberg M
    Clin Nephrol; 1990 Nov; 34(5):230-5. PubMed ID: 2268981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between blood pressure and renin, angiotensin II and atrial natriuretic factor after renal transplantation.
    Hestin D; Mertes PM; Hubert J; Claudon M; Mejat E; Renoult E; Pertek JP; Frimat L; Burlet C; Kessler M
    Clin Nephrol; 1997 Aug; 48(2):98-103. PubMed ID: 9285146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Renin-angiotensin system stimulates erythropoietin secretion in chronic hemodialysis patients.
    Vlahakos DV; Balodimos C; Papachristopoulos V; Vassilakos P; Hinari E; Vlachojannis JG
    Clin Nephrol; 1995 Jan; 43(1):53-9. PubMed ID: 7697936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical efficacy of recombinant human erythropoietin in hemodialysis patients.
    Mohini R
    Semin Nephrol; 1989 Mar; 9(1 Suppl 1):16-21. PubMed ID: 2648516
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effect of recombinant human erythropoietin administration on cardiovascular system in patient with chronic renal failure: an analysis of the blood pressure upward].
    Satoh K; Ikeda Y; Kurokawa S; Kamata K; Masuda T; Kikawada R; Marumo F
    Kokyu To Junkan; 1989 Mar; 37(3):313-9. PubMed ID: 2734509
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Echocardiographic findings in hemodialysis patients treated with recombinant human erythropoietin: proposal for a hematocrit most beneficial to hemodynamics.
    Tagawa H; Nagano M; Saito H; Umezu M; Yamakado M
    Clin Nephrol; 1991 Jan; 35(1):35-8. PubMed ID: 2007294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Recombinant human erythropoietin: 18 months of continuous use in substitution hemodialysis].
    Canaud B; Polito-Bouloux C; Rivory JP; Donnadieu P; Taib J; Florence P; Mion C
    Nephrologie; 1990; 11(1):5-10. PubMed ID: 2374643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormones in patients on continuous ambulatory peritoneal dialysis.
    Lai KN; Lui SF; Leung JC; Law E; Nicholls MG
    Nephron; 1991; 57(4):394-400. PubMed ID: 1828543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of normal hematocrit on ambulatory blood pressure in epoetin-treated hemodialysis patients with cardiac disease.
    Berns JS; Rudnick MR; Cohen RM; Bower JD; Wood BC
    Kidney Int; 1999 Jul; 56(1):253-60. PubMed ID: 10411700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of long-term erythropoietin therapy on endocrine abnormalities in haemodialyzed patients.
    Kokot F; Wiecek A; Schmidt-Gayk H; Marcinkowski W; Nieszporek T; Rudka R; Trembecki J
    Przegl Lek; 1992; 49(1-2):43-9. PubMed ID: 1455006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolonged protective effect of short daily hemodialysis against dialysis-induced hypotension.
    Okada K; Abe M; Hagi C; Maruyama T; Maruyama N; Ito K; Higuchi T; Matsumoto K; Takahashi S
    Kidney Blood Press Res; 2005; 28(2):68-76. PubMed ID: 15677874
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pressor effect of recombinant human erythropoietin: results of home blood pressure measurements in hemodialysis patients.
    Imai Y; Fujikura Y; Minami N; Munakata M; Hashimoto J; Sakuma H; Watanabe N; Nishiyama A; Misawa S; Sekino H
    Nihon Jinzo Gakkai Shi; 1994 Jan; 36(1):51-6. PubMed ID: 8107309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in endothelial vasoactive substances under recombinant human erythropoietin therapy in hemodialysis patients.
    Takayama K; Nagai T; Kinugasa E; Akizawa T; Koshikawa S
    ASAIO Trans; 1991; 37(3):M187-8. PubMed ID: 1836334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of low dose erythropoietin: a possible advantage of high flux hemodialysis.
    Depner TA; Rizwan S; James LA
    ASAIO Trans; 1990; 36(3):M223-5. PubMed ID: 2252662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Change in haemoglobin concentration, haematocrit and vasoactive hormones in haemodialysis patients with erythropoietin-associated hypertension.
    Sasagawa I; Nakada T; Hashimoto T; Kubota Y; Suzuki H; Sawamura T
    Int Urol Nephrol; 1994; 26(2):237-43. PubMed ID: 8034437
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A clinical study of persistent hypotension in patients on chronic hemodialysis].
    Tajiri M
    Nihon Jinzo Gakkai Shi; 1993 Mar; 35(3):223-31. PubMed ID: 8501851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Disordered alpha 2-adrenoreceptor function in hemodialysis patients with renal anemia--a possible cause of increased blood pressure in relation to recombinant human erythropoietin?].
    Müller R; Steffen HM; Brunner R; Pollok M; Baldamus CA; Kaufmann W
    Klin Wochenschr; 1991 Oct; 69(16):742-8. PubMed ID: 1662322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response of vasoactive substances to intermittent ultrafiltration in normotensive hemodialysis patients.
    Heintz B; Königs F; Dakshinamurty KV; Kierdorf H; Gladziwa U; Kirsten R; Nelson K; Wieland D; Riehl J; Mann H
    Nephron; 1993; 65(2):266-72. PubMed ID: 8247191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Changes in endothelial vasoactive substances and blood coagulation and fibrinolysis functions under recombinant human erythropoietin therapy in hemodialysis patients].
    Takayama K
    Nihon Jinzo Gakkai Shi; 1993 Feb; 35(2):179-88. PubMed ID: 8315881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.